Cardiac effects of sodium stibogluconate

Area of Science:

• Cardiology
• Pharmacology
• Infectious Diseases

Background:

• Sodium stibogluconate is the primary treatment for Kala-azar and cutaneous leishmaniasis.
• Concerns exist regarding its potential cardiotoxicity, necessitating further investigation.
• Increased usage in military settings prompted a formal cardiac safety evaluation.

Purpose of the Study:

• To assess the cardiac side effects of sodium stibogluconate in male soldiers.
• To evaluate the drug's impact on cardiovascular function using non-invasive methods.

Main Methods:

• A study involving 22 male soldiers receiving intravenous sodium stibogluconate (600 mg daily for 10 days).
• Utilized modern non-invasive techniques to monitor cardiac function.
• Included electrocardiography (ECG) to assess heart rhythm and electrical activity.

Main Results:

• No significant changes were observed in blood pressure, heart rate, or left ventricular contractile function.
• No adverse effects on cardiac rhythm were detected.
• Electrocardiography demonstrated a reversible reduction in T wave amplitude.

Conclusions:

• Sodium stibogluconate, at the studied dosage and duration, did not induce significant cardiotoxicity in male soldiers.
• The observed T wave amplitude reduction was temporary and reversible.
• Findings support the continued use of sodium stibogluconate for leishmaniasis treatment with careful cardiac monitoring.